<DOC>
	<DOCNO>NCT01664494</DOCNO>
	<brief_summary>This multi-center observational study evaluate use Xeloda ( capecitabine ) patient metastatic colorectal cancer , colon cancer adjuvant setting , advance gastric cancer breast cancer routine clinical practice . Eligible patient receive treatment Xeloda accord product label follow 10 month .</brief_summary>
	<brief_title>An Observational Study Xeloda ( Capecitabine ) Patients With Metastatic Colorectal Cancer , Colon Cancer Adjuvant Setting , Advanced Gastric Cancer Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Patients metastatic colorectal cancer , colon cancer adjuvant setting , advance gastric cancer breast cancer candidate receive Xeloda accord product label Contraindications accord label offlabel use</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>